Guardian Pharmacy Services (NYSE:GRDN) Posts Earnings Results, Beats Expectations By $0.03 EPS

Guardian Pharmacy Services (NYSE:GRDN) announced its earnings results on Thursday. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.26 by $0.03, FiscalAI reports. Guardian Pharmacy Services had a net margin of 4.50% and a return on equity of 31.45%. The firm had revenue of $351.77 million during the quarter, compared to analyst estimates of $340.45 million.

Here are the key takeaways from Guardian Pharmacy Services’ conference call:

• Guardian raised its 2026 outlook, now expecting revenue of $1.43 billion–$1.45 billion and adjusted EBITDA of $129 million–$131 million, up from prior ranges of $1.40 billion–$1.42 billion and $123 million–$127 million, respectively.
• Second-quarter adjusted EBITDA increased 19% to $29.7 million, supported by an 18% increase in gross profit, favorable product and payer mix, purchasing leverage, labor productivity, and operating efficiencies.
• The company reported continued operating expansion, including high-single-digit growth in residents served and script volumes, the acquisition of Wellness Concepts in Virginia, and the launch of a greenfield pharmacy in Lexington, Kentucky.
• Guardian said IRA-related pricing reductions will continue to pressure reported revenue, with second-half revenue expected to decline year over year by a low-single-digit percentage; management expects underlying revenue growth to remain in the high-single digits and believes the margin impact has been mitigated.
• Approximately 13.5 million Class B shares are expected to convert into Class A shares in late September, and 35 million–37 million employee, management, and director-held Class A shares could become eligible for sale after the next trading window following the third-quarter results, creating a potential supply overhang.

Guardian Pharmacy Services Trading Up 9.8%

Shares of NYSE:GRDN traded up $3.88 on Friday, reaching $43.35. 1,045,061 shares of the company’s stock were exchanged, compared to its average volume of 277,924. Guardian Pharmacy Services has a twelve month low of $19.30 and a twelve month high of $47.02. The company has a fifty day moving average of $40.93 and a 200-day moving average of $37.09. The company has a market capitalization of $2.16 billion, a price-to-earnings ratio of 42.09, a PEG ratio of 2.59 and a beta of 0.10.

Institutional Investors Weigh In On Guardian Pharmacy Services

A number of large investors have recently added to or reduced their stakes in GRDN. Boston Partners raised its stake in Guardian Pharmacy Services by 418.7% in the third quarter. Boston Partners now owns 1,046,877 shares of the company’s stock valued at $26,922,000 after purchasing an additional 845,048 shares in the last quarter. Loomis Sayles & Co. L P acquired a new stake in Guardian Pharmacy Services during the fourth quarter worth about $19,126,000. Millennium Management LLC grew its stake in Guardian Pharmacy Services by 725.2% during the third quarter. Millennium Management LLC now owns 342,038 shares of the company’s stock worth $8,972,000 after buying an additional 300,587 shares in the last quarter. Valiant Capital Management L.P. increased its holdings in Guardian Pharmacy Services by 15.8% in the 4th quarter. Valiant Capital Management L.P. now owns 1,232,463 shares of the company’s stock valued at $37,085,000 after buying an additional 167,741 shares during the period. Finally, Bank of America Corp DE increased its holdings in Guardian Pharmacy Services by 323.3% in the 3rd quarter. Bank of America Corp DE now owns 206,143 shares of the company’s stock valued at $5,407,000 after buying an additional 157,440 shares during the period.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on GRDN shares. Oppenheimer upped their price objective on Guardian Pharmacy Services from $43.00 to $49.00 and gave the stock an “outperform” rating in a research report on Friday. Truist Financial lifted their target price on Guardian Pharmacy Services from $43.00 to $47.00 and gave the company a “buy” rating in a research report on Wednesday, June 17th. Wall Street Zen cut shares of Guardian Pharmacy Services from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Weiss Ratings upgraded shares of Guardian Pharmacy Services from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday. Finally, Bank of America raised their target price on shares of Guardian Pharmacy Services from $42.00 to $47.00 and gave the company a “buy” rating in a research report on Wednesday, June 17th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Guardian Pharmacy Services presently has an average rating of “Moderate Buy” and a consensus target price of $43.83.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.